Perifosine (KRX-0401)

Name: Perifosine (KRX-0401)
Brand: Selleck Chemicals
SKU: S1037
Rating: 5 (155 reviews)

For research use only.

Catalog No.S1037 Synonyms: NSC639966, D21266

155 publications

Perifosine (KRX-0401) Chemical Structure

CAS No. 157716-52-4

Perifosine (KRX-0401, NSC639966, D21266) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Selleck's Perifosine (KRX-0401) has been cited by 155 publications

Cancer Cell, 2013, 23(6):839-52

PubMed: 23684459 ( click the link to review the publication )

Cell, 2012, 149(3):656-70

PubMed: 22920938 ( click the link to review the publication )

J Clin Endocrinol Metab, 2021, dgab020

PubMed: 33524147 ( click the link to review the publication )

IUBMB Life, 2021, 10.1002/iub.2514

PubMed: 34110086 ( click the link to review the publication )

Oncol Rep, 2021, 46(3)202

PubMed: 34296295 ( click the link to review the publication )

Eur J Pharmacol, 2021, 898:173957

PubMed: 33662352 ( click the link to review the publication )

Cardiovasc Toxicol, 2021, 21(8):655-668

PubMed: 34021461 ( click the link to review the publication )

Aging (Albany NY), 2020, 18;12(10):9489-9499

PubMed: 32421688 ( click the link to review the publication )

Front Oncol, 2020, 10:584505

PubMed: 33425737 ( click the link to review the publication )

Toxicol Sci, 2020, kfaa159

PubMed: 33078829 ( click the link to review the publication )

Front Microbiol, 2020, 11:565590

PubMed: 33042070 ( click the link to review the publication )

Cancer Cell Int, 2020, 25;20:134

PubMed: 32351328 ( click the link to review the publication )

J Cell Biochem, 2020, 121(1):723-734

PubMed: 31452248 ( click the link to review the publication )

Transl Oncol, 2020, 13(2):355-364

PubMed: 31887630 ( click the link to review the publication )

Cell Stress Chaperones, 2020, 9

PubMed: 32519137 ( click the link to review the publication )

Biosci Rep, 2020, BSR20201539

PubMed: 33269380 ( click the link to review the publication )

Commun Biol, 2020, 3(1):378

PubMed: 32665601 ( click the link to review the publication )

Sci Rep, 2020, 10(1):10315

PubMed: 32587277 ( click the link to review the publication )

Chin J Integr Med, 2020, 10.1007

PubMed: 31903532 ( click the link to review the publication )

Dev Cell, 2019, 51(2):236-254

PubMed: 31543445 ( click the link to review the publication )

Dev Cell, 2019, 50(2):229-246

PubMed: 31204173 ( click the link to review the publication )

Cancer Lett, 2019, 447:93-104

PubMed: 30660646 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5334

PubMed: 31397884 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31627436 ( click the link to review the publication )
Cancers (Basel), 2019, 11(12)

PubMed: 31769426 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(2):356-363

PubMed: 30446585 ( click the link to review the publication )

Cell Prolif, 2019, 52(5):e12638

PubMed: 31152465 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.28205

PubMed: 30706473 ( click the link to review the publication )

Front Oncol, 2019,

PubMed: 31850228 ( click the link to review the publication )

Front Oncol, 2019, 9:422

PubMed: 31192127 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31767884 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 381:114729

PubMed: 31445927 ( click the link to review the publication )

J Cell Biochem, 2019, 10.1002/jcb.28410

PubMed: 30724378 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 511(3):559-565

PubMed: 30824188 ( click the link to review the publication )

Mol Med Rep, 2019, 20(1):33-40

PubMed: 31115502 ( click the link to review the publication )

Med Sci Monit, 2019, 25:7218-7227

PubMed: 31554782 ( click the link to review the publication )

Redox Biol, 2018, 16:47-58

PubMed: 29475134 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):747

PubMed: 29970878 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):911

PubMed: 30185800 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):739

PubMed: 29970892 ( click the link to review the publication )

Front Aging Neurosci, 2018, 10:378

PubMed: 30515090 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):828-840

PubMed: 29344641 ( click the link to review the publication )

J Cell Biochem, 2018, 119(12):9997-10004

PubMed: 30145830 ( click the link to review the publication )

Chem Res Toxicol, 2018, 31(11):1219-1229

PubMed: 30265530 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(8):748-756

PubMed: 29961813 ( click the link to review the publication )

BMC Neurosci, 2018, 19(1):52

PubMed: 30189852 ( click the link to review the publication )

Cell Biol Int, 2018, 42(8):959-964

PubMed: 29569784 ( click the link to review the publication )

Mol Med Rep, 2018, 18(1):447-454

PubMed: 29749519 ( click the link to review the publication )
Neoplasma, 2018, 65(5):701-707

PubMed: 29940761 ( click the link to review the publication )

Transl Cancer Res, 2018, 7(6):1548-1560

PubMed: 30761266 ( click the link to review the publication )

J Pharm Pharmacol, 2018, 70(2):259-267

PubMed: 29148068 ( click the link to review the publication )

Oncotarget, 2018, 9(10):9425-9441

PubMed: 29507700 ( click the link to review the publication )

Oncotarget, 2018, 9(15):12261-12272

PubMed: 29552308 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(3):238-251

PubMed: 28218907 ( click the link to review the publication )

Nat Commun, 2017, 8:14091

PubMed: 28345588 ( click the link to review the publication )

Autophagy, 2017, 13(8):1364-1385

PubMed: 28598230 ( click the link to review the publication )

Sci Rep, 2017, 7:45136

PubMed: 28332584 ( click the link to review the publication )

Am J Pathol, 2017, 187(8):1736-1749

PubMed: 28627412 ( click the link to review the publication )

Mediators Inflamm, 2017, 2017:5706152

PubMed: 29056830 ( click the link to review the publication )

PLoS One, 2017, 12(3):e0173473

PubMed: 28291820 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0169585

PubMed: 28081222 ( click the link to review the publication )

Med Sci Monit, 2017, 23:5637-5649

PubMed: 29176544 ( click the link to review the publication )

Biotechnol Lett, 2017, 39(9):1343-1349

PubMed: 28597147 ( click the link to review the publication )

Int J Clin Exp Pathol, 2017, 10(9):9400-9408

PubMed: 31966812 ( click the link to review the publication )

Oncotarget, 2017, 8(19):31666-31681

PubMed: 28427224 ( click the link to review the publication )

Oncotarget, 2017, 8(2):2594-2603

PubMed: 27911877 ( click the link to review the publication )

Oncotarget, 2017, 8(38):63911-63922

PubMed: 28969040 ( click the link to review the publication )

Sci Rep, 2017, 7:42062

PubMed: 28165023 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

J Clin Invest, 2016, 126(4):1300-10

PubMed: 26927669 ( click the link to review the publication )

Nucleic Acids Res, 2016, 45(6):3130-3145

PubMed: 27980063 ( click the link to review the publication )

Cell Death Dis, 2016, 7:e2043

PubMed: 26775697 ( click the link to review the publication )
Mol Cancer Ther, 2016, 15(7):1504-14

PubMed: 27196761 ( click the link to review the publication )

Biomed Pharmacother, 2016, 84:305-313

PubMed: 27665476 ( click the link to review the publication )

Exp Cell Res, 2016, 340(1):81-90

PubMed: 26712518 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 479(1):54-60

PubMed: 27614310 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 473(4):1170-6

PubMed: 27073162 ( click the link to review the publication )

J Mol Neurosci, 2016, 59(4):567-78

PubMed: 27412469 ( click the link to review the publication )

Anticancer Res, 2016, 36(11):5849-5858

PubMed: 27793908 ( click the link to review the publication )

Oncotarget, 2016, 7(24):36971-36987

PubMed: 27175591 ( click the link to review the publication )

Oncotarget, 2016, 7(16):22687-99

PubMed: 27007150 ( click the link to review the publication )

NPJ Syst Biol Appl, 2016, 2:16027

PubMed: 28725479 ( click the link to review the publication )

Tumour Biol, 2016, 37(1):1025-33

PubMed: 26269112 ( click the link to review the publication )

Biochem Pharmacol, 2015, 10.1016/j.bcp.2015.04.015

PubMed: 25934232 ( click the link to review the publication )

Sci Rep, 2015, 5:12059

PubMed: 26154270 ( click the link to review the publication )

Oncol Rep, 2015, 33(2):875-84

PubMed: 25484022 ( click the link to review the publication )

Mol Cell Biochem, 2015, 398(1-2):105-13

PubMed: 25223639 ( click the link to review the publication )

Growth Horm IGF Res, 2015, 25(3):115-20

PubMed: 25900365 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: 25269544 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(4):557-62

PubMed: 25712742 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(30):29963-74

PubMed: 26298773 ( click the link to review the publication )

Oncoscience, 2015, 2(4):395-409

PubMed: 26097873 ( click the link to review the publication )

Oncoscience, 2015, 2(4):382-94

PubMed: 26097872 ( click the link to review the publication )

Crit Rev Oncol Hematol, 2015,

PubMed: 26253360 ( click the link to review the publication )

Oncotarget, 2015, 6(9):6597-610

PubMed: 25788264 ( click the link to review the publication )
Oncoscience, 2015,

PubMed: ( click the link to review the publication )

Oncoscience, 2015, 10.1155/2015/8332

PubMed: ( click the link to review the publication )

Tumour Biol, 2015, 10.1007/s13277-015-3244-2

PubMed: 25697899 ( click the link to review the publication )

Cancer Res, 2014, 74(16):4458-69

PubMed: 24934808 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.184.

PubMed: 24998847 ( click the link to review the publication )

FASEB J, 2014, 27(7):2584-99

PubMed: 23507869 ( click the link to review the publication )

Cardiovasc Diabetol, 2014, 35(7):450-4

PubMed: 24836459 ( click the link to review the publication )

Carcinogenesis, 2014, 35(10):2232-43

PubMed: 24942865 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(9):1851-64

PubMed: 24769208 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02798-13

PubMed: 24752266 ( click the link to review the publication )

Anal Bioanal Chem, 2014, 406(15):3743-54

PubMed: 24817345 ( click the link to review the publication )

Pediatr Res, 2014, 75(4):527-34

PubMed: 24366516 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Biomed Res Int, 2014, 2014:568693

PubMed: 25309914 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 453(3):362-7

PubMed: 25264192 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(1):72-8

PubMed: 25152399 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 450(1):646-51

PubMed: 24946212 ( click the link to review the publication )

Vet J, 2014, 201(1):83-90

PubMed: 24881508 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Cell Logist, 2014, 4(1):e27732

PubMed: 24843827 ( click the link to review the publication )

Oncotarget, 2014, 5(14):5295-303

PubMed: 24979463 ( click the link to review the publication )

Rostock University, 2014, Lange F

PubMed: ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )
Cancer Lett, 2013, 336(2):319-24

PubMed: 23528835 ( click the link to review the publication )

Gynecol Oncol, 2013, 131(1):207-12

PubMed: 23877012 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1831(8):1322-34

PubMed: 23707264 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1828(5):1384-9

PubMed: 23376656 ( click the link to review the publication )

Sci Rep, 2013, 3:1697

PubMed: 23603888 ( click the link to review the publication )

J Biol Chem, 2013, 288(31):22836-48

PubMed: 23788636 ( click the link to review the publication )

Mol Pharmacol, 2013, 84(4):562-71

PubMed: 23877009 ( click the link to review the publication )

Biochimie, 2013, 101:50-9

PubMed: 24394624 ( click the link to review the publication )

Oncol Rep, 2013, 29(6):2422-30

PubMed: 23588929 ( click the link to review the publication )

Biochemistry, 2013, 53(3):462-72

PubMed: 24383815 ( click the link to review the publication )

Dig Dis Sci, 2013, 58(10):2873-80

PubMed: 23912246 ( click the link to review the publication )

PLoS One, 2013, 8(5):e61896

PubMed: 23658701 ( click the link to review the publication )

PLoS One, 2013, 8(8): e74420

PubMed: 24009772 ( click the link to review the publication )

PLoS One, 2013, 8(8): e70804

PubMed: 23936469 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 443(2):447-52

PubMed: 24316214 ( click the link to review the publication )

Mol Biol Rep, 2013, 40(10):5645-55

PubMed: 24065522 ( click the link to review the publication )

Mol Med Rep, 2013, 7(2):642-8

PubMed: 23175237 ( click the link to review the publication )

Cell Biochem Biophys, 2013, 66(3):737-46

PubMed: 23397419 ( click the link to review the publication )

Cell Biochem Biophys, 2013, 65(2):217-27

PubMed: 23015227 ( click the link to review the publication )

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

Cancer Res, 2012, 72(10):2622-33

PubMed: 22461507 ( click the link to review the publication )

J Clin Endocrinol Metab, 2012, 97(2):E173-82

PubMed: 22090271 ( click the link to review the publication )

Mol Cell Proteomics, 2012, 11(12):1898-912

PubMed: 23001822 ( click the link to review the publication )

J Biol Chem, 2012, 286(43):37389-98

PubMed: 21908616 ( click the link to review the publication )
Expert Opin Inv Drugs, 2012, 21(11):1597-606

PubMed: ( click the link to review the publication )

Mol Carcinog, 2012, 52(9):667-75

PubMed: 22488590 ( click the link to review the publication )

Surgery, 2012, 152(6):1218-24

PubMed: 23158188 ( click the link to review the publication )

Cancer Biol Ther, 2012, 13(11):1009-17

PubMed: 22825337 ( click the link to review the publication )

PLoS Biol, 2011, 9(9):e1001148

PubMed: 21931533 ( click the link to review the publication )

Cancer Lett, 2011, 310(1):118-28

PubMed: 21775054 ( click the link to review the publication )

J Pharmacol Exp Ther, 2011, 336(3):866-73

PubMed: 21148684 ( click the link to review the publication )

Radiat Oncol, 2011, 6:39

PubMed: 21496273 ( click the link to review the publication )

Cancer Res, 2010, 70(22):9106-17

PubMed: 21062988 ( click the link to review the publication )

Brit J Pharmacol, 2010, 160(2):355-66

PubMed: 20423345 ( click the link to review the publication )

Cytotechnology, 2010, 62(5):449-60

PubMed: 20842425 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description

Perifosine (KRX-0401, NSC639966, D21266) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Targets

Akt ^[1]
(MM.1S cells)

4.7 μM

In vitro

Perifosine develops anti-proliferative properties with IC50 of 0.6-8.9 μM in immortalized keratinocytes (HaCaT), and head and neck squamous carcinoma cells. ^[1] Perifosine strongly reduces phosphorylation levels of Akt and extracellular signal-regulated kinase (Erk) 1/2, induces cell cycle arrest in G1 and G2, and causes dose-dependent growth inhibition of mouse glial progenitors. ^[2] Perifosine (10 μM) completely inhibits the phosphorylation of Akt in MM.1S cells. ^[3] A recent study demonstrates Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
HL-60	M2HyTWFxd3C2b4Ppd{BCe3O\|YYm=	NILuWJkyOMLizszN	NH2xOJUzPC92ODDo	NWH4Rm8{cW6mdXPld{BieG:ydH;zbZMhfGmvZT3k[ZBmdmSnboTsfS=>	NIXYb3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEGzNFk3OCd-MkCxN\|A6PjB:L3G+
MOLM	MVnBdI9xfG:\|aYOgRZN{e2G7	MmXpNVDDqM7:TR?=	MV:yOE81QCCq	NIHDWolqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5	M1rwS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUOwPVYxLz5{MEGzNFk3ODxxYU6=
OCI	NETyVnVCeG:ydH;zbZMhSXO\|c3H5	MWWxNOKh\|ryP	NG\UNFkzPC92ODDo	NFnDOXRqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF\|MEm2NEc,OjBzM{C5OlA9N2F-
BJAB	NYjG[plJSXCxcITvd4l{KEG\|c4PhfS=>	NFnEcGYyOMLizszN	NEPVS2MzPC92ODDo	NVLwNpRwcW6mdXPld{BieG:ydH;zbZMhfGmvZT3k[ZBmdmSnboTsfS=>	NGjXeVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEGzNFk3OCd-MkCxN\|A6PjB:L3G+
MAVER	MkLvRZBweHSxc3nzJGF{e3OjeR?=	M4\KUlExyqEQvF2=	Ml6yNlQwPDhiaB?=	MV\pcoR2[2W\|IHHwc5B1d3OrczD0bY1mNWSncHXu[IVvfGy7	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF\|MEm2NEc,OjBzM{C5OlA9N2F-
SKW6.4	NXG4N5NoSXCxcITvd4l{KEG\|c4PhfS=>	MX:xNOKh\|ryP	MkPNNlQwPDhiaB?=	MVTpcoR2[2W\|IHHwc5B1d3OrczD0bY1mNWSncHXu[IVvfGy7	MkS0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzM{C5OlAoRjJyMUOwPVYxRC:jPh?=
HL-60	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mof1Nk0yOMLizszN	M2DTNFQ5yqCq	NX6wXHo6cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	M4Tq[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUOwPVYxLz5{MEGzNFk3ODxxYU6=
MOLM	MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzrNk0yOMLizszN	MmTmOFjDqGh?	M3z4TolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	NFTjZpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEGzNFk3OCd-MkCxN\|A6PjB:L3G+
OCI	M3jReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIW2PJczNTFywrFOwG0>	M3\0XlQ5yqCq	M1juXIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	M{\GV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUOwPVYxLz5{MEGzNFk3ODxxYU6=
BJAB	M1HTXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVeyMVExyqEQvF2=	MoPOOFjDqGh?	NFHTNHdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NIPLUpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEGzNFk3OCd-MkCxN\|A6PjB:L3G+
MAVER	M2TNVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWO4WnBCOi1zMNMg{txO	NFXrcXg1QMLiaB?=	NXfMcGZ[cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	M1jOTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUOwPVYxLz5{MEGzNFk3ODxxYU6=
SKW6.4	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3:4dFIuOTEEoN88US=>	NHvweno1QMLiaB?=	MWPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	M{HndVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUOwPVYxLz5{MEGzNFk3ODxxYU6=
A2780cis	M1nmXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HyVVAuOjBizszN	MkXnOFgwPzJiaB?=	NGDsVIZKSzVywrC9xsA3yqEQvH2=	MnLjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2MEWyPVYoRjJyNEC1Nlk3RC:jPh?=
A2780	NHLCXotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4KxTFAuOjBizszN	NGrKWIM1QC95MjDo	NFvIc\|RKSzVywrC9xsA{yqEQvH2=	NWTyeIZWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0NFUzQTZpPkKwOFA2Ojl4PD;hQi=>
SKOV3	NYfLdHNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHn5ZVYxNTRyIN88US=>	MUi3NuKhcA>?	MnfKTWM2OH5\|MDFOwG0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	NXywNFFtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0NFUzQTZpPkKwOFA2Ojl4PD;hQi=>
PA-1	MnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUGwMVQxKM7:TR?=	M1rvcFczyqCq	NInVcFRKSzVyfkK1JO69VSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MoPWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2MEWyPVYoRjJyNEC1Nlk3RC:jPh?=
OAW-42	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFm4UW8xNTRyIN88US=>	M{\nUFczyqCq	NWP2RW5UUUN3MI6xNEDPxE1uIHnubIljcXS\|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	MmfoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2MEWyPVYoRjJyNEC1Nlk3RC:jPh?=
Bel-7402	M4jjNmFxd3C2b4Ppd{BCe3O\|YYm=	M4DHdVUwOTBxMkCg{txO	NX7sdGYxOjRxNEigbC=>	NFLjPYdqdmS3Y3XzJIFxd3C2b4Ppd{BifCC2aHWgcI9v\y22aX3lJIV5eG:\|dYLl	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh2MkSyOUc,OjB6NEK0NlU9N2F-
HepG2	NHzkRXlCeG:ydH;zbZMhSXO\|c3H5	NH3hWZM2NzFyL{KwJO69VQ>?	NYmxd\|VrOjRxNEigbC=>	M33LWIlv\HWlZYOgZZBweHSxc3nzJIF1KHSqZTDsc45oNXSrbXWg[Zhxd3O3cnW=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh2MkSyOUc,OjB6NEK0NlU9N2F-
Bel-7402	M1vu[GZ2dmO2aX;uJGF{e2G7	NF7kWYM2NzFyL{KwJO69VQ>?	Mlj2NlQhcA>?	MnLBdoV{fWy2czDpckB1cGViYXPjeY12dGG2aX;uJI9nKGOnbHygcpVu[mW{IHnuJJRp\SCJMj;NJJBp[XOn	NYTWPYNmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4OFI1OjVpPkKwPFQzPDJ3PD;hQi=>
HepG2	NYH4eYplTnWwY4Tpc44hSXO\|YYm=	Mn;LOU8yOC9{MDFOwG0>	M4rRTFI1KGh?	NVvHPVJuemW\|dXz0d{BqdiC2aHWgZYNkfW23bHH0bY9vKG:oIHPlcIwhdnWvYnXyJIlvKHSqZTDHNk9OKHCqYYPl	M1vNVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOESyOFI2Lz5{MEi0NlQzPTxxYU6=
Bel-7402	MmHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXy1M\|ExNzJyL{SwJO69VQ>?	MonYNlQwPDhxN{KgbC=>	NFfLPZhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	M1;1c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOESyOFI2Lz5{MEi0NlQzPTxxYU6=
HepG2	NGL5R25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlGxOU8yOC9{MD:0NEDPxE1?	MXqyOE81QC95MjDo	NH7SUGxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	NXnSRoh2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4OFI1OjVpPkKwPFQzPDJ3PD;hQi=>
CWR22RV1	NVrJfHp[TnWwY4Tpc44hSXO\|YYm=	M{L0c\|Uh\|ryP	NWj1cHFDOjRiaB?=	NFvtTmlz\WS3Y3XkJJBpd3OyaH;yfYxifGmxbjDv[kBCc3Ric3nncolncWOjboTsfS=>	NGXUbXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS5OlI4Oyd-MkG0PVYzPzN:L3G+
CWR22RV1	M4HZPGFxd3C2b4Ppd{BCe3O\|YYm=	NVrLN2w1OTBizszN	NYPRNGpvOjRiaB?=	MVflcohidmOnczDyZYRq[XSrb36gbY5lfWOnZDDhdI9xfG:\|aYO=	M3nDSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEm2Nlc{Lz5{MUS5OlI4OzxxYU6=
CWR22RV1	MUjD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MoP4NVAh\|ryP	NWfIR4VWOjRiaB?=	M2XO[olv[3KnYYPld{B{\W6\|aYTpeol1gSCxZjDoeY1idiCFV2KyNnJXOSClZXzsd{B1dyC{YXTpZZRqd25?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR7NkK3N{c,OjF2OU[yO\|M9N2F-
A498	NWXuN\|ZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF76XYgxNTJyIN88US=>	NYDMZW5CPzJiaB?=	NHK2N25qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NUHxTVdYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG2OFQxPTBpPkKxOlQ1ODVyPD;hQi=>
769-P	NEfoTodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV:5OGwyOC1{MDFOwG0>	M1fPOlczKGh?	NYPYXol7cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NW\BdW12RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG2OFQxPTBpPkKxOlQ1ODVyPD;hQi=>
CAKI-1	NELnNYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1q3clAuOjBizszN	M1LLUlczKGh?	M{S1XIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTZ2NEC1NEc,OjF4NESwOVA9N2F-
786-O	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rwOVAuOjBizszN	NIL3T4g4OiCq	NFzU[o1qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NUPm[Zc4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG2OFQxPTBpPkKxOlQ1ODVyPD;hQi=>
786-0	NGPSXXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPjd3QxNTRyIN88US=>	NYj3b5F2PzJiaB?=	NY\ScG93UUN3MI61JO69VQ>?	MoPrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF4NESwOVAoRjJzNkS0NFUxRC:jPh?=
769-P	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXLXWxZOC12MDFOwG0>	MXi3NkBp	MnvPTWM2OH53LUGwJO69VQ>?	NF\WPI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MU[0OFA2OCd-MkG2OFQxPTB:L3G+
CAKI-1	M4LIUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfrW3UxNTRyIN88US=>	M4\mTVczKGh?	M1\ySWlEPTC-MUCg{txO	NHr4WZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MU[0OFA2OCd-MkG2OFQxPTB:L3G+
A498	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV:wMVQxKM7:TR?=	NWjueIFVPzJiaB?=	M1Sx[4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	MoDlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF4NESwOVAoRjJzNkS0NFUxRC:jPh?=
HT-29	M{Sz[GN6fG:2b4jpZ4l1gSCDc4PhfS=>	M1e0[\|Uh\|ryP	NID4dmc1QCCq	M2\HS4VvcGGwY3XzJJBi[2yrdHH4[YwhcW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA>	NXrOZnFuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O\|UxPTRpPkKxO\|c2ODV2PD;hQi=>
A2780	MknzR5l1d3SxeHnjbZR6KEG\|c3H5	NVrXO4tVPSEQvF2=	Mnv5OFghcA>?	NVuwTZVx\W6qYX7j[ZMheGGlbHn0ZZhmdCCrbnT1Z4VlKG:4YYLpZY4h[2GwY3XyJINmdGxiZHXheIjDqA>?	M4ntNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{e1NFU1Lz5{MUe3OVA2PDxxYU6=
SKOV3	NGf4fmtEgXSxdH;4bYNqfHliQYPzZZk>	MWe1JO69VQ>?	NXr3T4V2PDhiaB?=	M4D1NYVvcGGwY3XzJJBi[2yrdHH4[YwhcW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA>	MljCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{WwOVQoRjJzN{e1NFU1RC:jPh?=
CaOV3	NHzDfHJE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NV3RbIJTOS93L{GwJO69VQ>?	NVnCNZh7PDhiaB?=	NVjGemxo\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXyJINwfHKnYYTl[EB4cXSqIIDhZ4xqfGG6ZXy=	MnPjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{WwOVQoRjJzN{e1NFU1RC:jPh?=
OCUT1	NF;JUItHfW6ldHnvckBCe3OjeR?=	NX7m[JNrOyEQvH2=	MmTLNlQhcA>?	M4\vSYNifXOnczDhJIRz[W2jdHnjJIlv[3KnYYPlJIlvKEd{L12gdIhie2V?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB7MEK3NUc,OjJyOUCyO\|E9N2F-
K1	NYDTPW92T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVmwMlEuOyEQvF2=	MofQOUBl	MXjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	NGPD[Hc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC5NFI4OSd-MkKwPVAzPzF:L3G+
OCUT1	NUDrSZY2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXjVotYOC5zLUOg{txO	MWq1JIQ>	M3zJOYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	M4HsSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEmwNlcyLz5{MkC5NFI4OTxxYU6=
K562	MYXGeY5kfGmxbjDBd5NigQ>?	NUXSOHBtOjBizszN	Mn2wOFghcA>?	NGjJbpFqdmS3Y3XzJIF2fG:yaHHnfeKh	NGPWTVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSwO\|IzQCd-MkK0NFczOjh:L3G+
HL-60	M2f5TmZ2dmO2aX;uJGF{e2G7	M3ztOVIvPS93L{GwJO69VQ>?	NYDDdmgyOjRiaB?=	NYO4bY9kcW6mdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFrOT\|EwOiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjRyN{KyPEc,OjJ2MEeyNlg9N2F-
Kasumi-1	Ml:3SpVv[3Srb36gRZN{[Xl?	NWrEdXZ3Oi53L{WvNVAh\|ryP	M33kSlI1KGh?	MnnFbY5lfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEqQS{GvNkBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	M1LvWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEC3NlI5Lz5{MkSwO\|IzQDxxYU6=
HL-60	NVjUXmdKTnWwY4Tpc44hSXO\|YYm=	NXfnbG5oOi53L{WvNVAh\|ryP	MYmyOEBp	NY\hV5o6\GWlcnXhd4V{KEGtdDDhcoQheC2Da4SgcIV3\Wy\|wrDkc5NmNWSncHXu[IVvfGy7	M{f4XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEC3NlI5Lz5{MkSwO\|IzQDxxYU6=
Kasumi-1	M2LKTmZ2dmO2aX;uJGF{e2G7	M{fOPVIvPS93L{GwJO69VQ>?	NGH1SnQzPCCq	MVLk[YNz\WG\|ZYOgRYt1KGGwZDDwMWFsfCCuZY\lcJPDqGSxc3Wt[IVx\W6mZX70cJk>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjRyN{KyPEc,OjJ2MEeyNlg9N2F-
HL-60	MYXBdI9xfG:\|aYOgRZN{e2G7	NHHMVW8yOCEQvF2=	MUOyOEBp	MoPObY5lfWOnczDhdI9xfG:\|aYO=	NHXGbWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSwO\|IzQCd-MkK0NFczOjh:L3G+
Kasumi-1	MV\BdI9xfG:\|aYOgRZN{e2G7	MUmxNEDPxE1?	M2Lre\|I1KGh?	NV\3V3I6cW6mdXPld{BieG:ydH;zbZM>	NEPF[Gg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSwO\|IzQCd-MkK0NFczOjh:L3G+
HL-60	MlPFR4VtdCCYaXHibYxqfHliQYPzZZk>	MUWwMVIxKM7:TR?=	MXGyOE81QCCq	NYTmV3Jj\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGKxdHig[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz	NIHRPGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSwO\|IzQCd-MkK0NFczOjh:L3G+
Kasumi-1	NH65[\|FE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NEXRSlAxNTJyIN88US=>	NVHvS2RMOjRxNEigbC=>	M3z2SIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=>	NFnZeYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSwO\|IzQCd-MkK0NFczOjh:L3G+
BON1	Mkf4SpVv[3Srb36gRZN{[Xl?	MkPCO{42NzFyIN88US=>	MYW4JIg>	M1rLTYRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kB1cGViYX70bU1ieG:ydH;0bYMheHKxdHXpcpMhSkOOMjDhcoQhSmOuLWjM	NFqwVmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS5PVQ{Pyd-MkK0PVk1Ozd:L3G+
BON1	MXPBdI9xfG:\|aYOgRZN{e2G7	NEK2VZIxNTFyIN88US=>	M{fGU\|I1KGh?	MXrpcoR2[2W\|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7	MofHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OUm0N\|coRjJ{NEm5OFM4RC:jPh?=
BON1	M4r5S2NmdGxiVnnhZoltcXS7IFHzd4F6	M1z2NVAuOTByIN88US=>	NV;1SVdDOjRxN{KgbC=>	MkXr[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy	Mlm2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OUm0N\|coRjJ{NEm5OFM4RC:jPh?=
GOT1	MnGxR4VtdCCYaXHibYxqfHliQYPzZZk>	M1zKV\|AuOTByIN88US=>	M1rLWlI1Nzd{IHi=	NFG2O5Nl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR7OUSzO{c,OjJ2OUm0N\|c9N2F-
NCI-H727	NIn5Z4pE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NXXGRmo1OC1zMECg{txO	MojoNlQwPzJiaB?=	MVjk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	Mm\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OUm0N\|coRjJ{NEm5OFM4RC:jPh?=
MCAS	NEXUeVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWDJR\|UxRTF{LkWg{txO	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh5N{CxNkc,OjN6N{ewNVI9N2F-
A2780S	MnHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NGO0dWVKSzVyPUG0MlUh\|ryP	Mlz4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6N{ewNVIoRjJ\|OEe3NFEzRC:jPh?=
OVCAR5	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVLJR\|UxRTZwNzFOwG0>	NXvUdGVuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4O\|cxOTJpPkKzPFc4ODF{PD;hQi=>
A2780CP	M2H0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MknPTWM2OD15Lk[g{txO	M364T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEe3NFEzLz5{M{i3O\|AyOjxxYU6=
HeyA8	NHf0VYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mkf5TWM2OD1{ND6zJO69VQ>?	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh5N{CxNkc,OjN6N{ewNVI9N2F-
OVCAR8	M{\DVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3;HNWlEPTB;M{GuNUDPxE1?	NULDb\|Q6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4O\|cxOTJpPkKzPFc4ODF{PD;hQi=>
M41R	NHOxWHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1\MSGlEPTB;MUmuPEDPxE1?	MlTPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6N{ewNVIoRjJ\|OEe3NFEzRC:jPh?=
M41	Mn7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHftXoFKSzVyPUK0Mlch\|ryP	MlLnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6N{ewNVIoRjJ\|OEe3NFEzRC:jPh?=
TykNuR	NXzJcolHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4\sVmlEPTB;NT61JO69VQ>?	NEPNeGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i3O\|AyOid-MkO4O\|cxOTJ:L3G+
TykNu	MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4TMUmlEPTB;Mz61JO69VQ>?	NG\ubWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i3O\|AyOid-MkO4O\|cxOTJ:L3G+
MGC803	NUCwWVk1TnWwY4Tpc44hSXO\|YYm=	NYWzZop2OC55NT:xNOKh\|ryP	NVPlV2NIPDkEoHi=	Mlnu[IVkemWjc3XzJJAuSWu2IDjT[ZIhPDd\|KTygdE1IW0t\|zsKgLHNmeiB7KTygZY5lKENvTWnDJIxmfmWuc9Mg	NInYOmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mxNlI1Pid-MkO5NVIzPDZ:L3G+
SGC7901	MUTGeY5kfGmxbjDBd5NigQ>?	NFXXVm0xNjd3L{GwxsDPxE1?	MW[0PEBp	NED2RZNl\WO{ZXHz[ZMheC2Da4SgLHNmeiB2N{OpMEBxNUeVS{ROtkApW2W{IEmpMEBidmRiQz3NXWMhdGW4ZXzzxsA>	NIPL[mo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mxNlI1Pid-MkO5NVIzPDZ:L3G+
U87MG	NYW3dGg4S2WubDDWbYFjcWyrdImgRZN{[Xl?	NIL5[mYxNTJ3IN88US=>	NGrNWIczPC17NjDo	M1nSWoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=>	MmjWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNkW1NlIoRjJ2ME[1OVIzRC:jPh?=
AsPC-1	MXjGeY5kfGmxbjDBd5NigQ>?	MXWwMlUh\|ryP	NU\jN\|lNOjRiaB?=	M4X1UolvcGmkaYTzJGFsfCxiU{\LNUwh[W6mIFXyb\|EwOiCyaH;zdIhwenmuYYTpc47DqA>?	M3HSflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUG5O\|UyLz5{NEWxPVc2OTxxYU6=
MIA	MXLGeY5kfGmxbjDBd5NigQ>?	NGTjXXExNjVizszN	NGXNcmMzPCCq	NIPvW5JqdmirYnn0d{BCc3RuIGO2T\|EtKGGwZDDFdosyNzJicHjvd5Bpd3K7bHH0bY9vyqB?	NVj1cHhPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1NVk4PTFpPkK0OVE6PzVzPD;hQi=>
PANC-1	NIG0VG9HfW6ldHnvckBCe3OjeR?=	NYOyZWJ4OC53IN88US=>	NGq0WogzPCCq	NHWzcHFqdmirYnn0d{BCc3RuIGO2T\|EtKGGwZDDFdosyNzJicHjvd5Bpd3K7bHH0bY9vyqB?	NWLNNYRzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1NVk4PTFpPkK0OVE6PzVzPD;hQi=>
AsPC-1	NILKVG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;pdFAuOjVizszN	M4\Ic\|czKGh?	MnrsbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	NXfGXoZHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1NVk4PTFpPkK0OVE6PzVzPD;hQi=>
MIA	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fVcFAuOjVizszN	MoH3O\|IhcA>?	M17wVIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	NVXSZWdERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1NVk4PTFpPkK0OVE6PzVzPD;hQi=>
PANC-1	MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzwXmExNTJ3IN88US=>	NIrjc4U4OiCq	M3rVfYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	MojNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3MUm3OVEoRjJ2NUG5O\|UyRC:jPh?=
Ema	MnLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVuwMlHjiJNzMEFihKnPxE1?	NV\k[m0yPDhiaB?=	M4Pwb2lEPTB;NUiuO{DPxE1?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh6MUWwPEc,OjR6OEG1NFg9N2F-
UL-1	M3z2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1L5clAvOeLCk{GwNQKBkc7:TR?=	Mo[yOFghcA>?	NWGxcpMxUUN3ME23MlAyKM7:TR?=	MmnrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OEG1NFgoRjJ2OEixOVA5RC:jPh?=
CLBL-1	NYC0VFFUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;XU2wxNjIkgKOxNFDjiIoQvF2=	NXrrNGZHPDhiaB?=	NHvWSWhKSzVyPUOzMlAh\|ryP	M2DaflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEixOVA5Lz5{NEi4NVUxQDxxYU6=
GL-1	MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{SwSVAvOeLCk{GwNQKBkc7:TR?=	M2joV\|Q5KGh?	MXXJR\|UxRTlwOUGg{txO	NUXyWo1DRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFE2ODhpPkK0PFgyPTB6PD;hQi=>
MDA-MB-231	Mn:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TzVlAuOTBizszN	NIjnVZc1QCCq	NUDRO2xjTUN3ME2xMlE{6oDLwsJihKkxNjB5IN88US=>	MmDMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OUO1O\|YoRjJ3MkmzOVc3RC:jPh?=
HCC1806	M4\JcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUewMVExKM7:TR?=	NVvNdIR6PDhiaB?=	MWHFR\|UxRTJwOEVihKnDueLCiUCuNFch\|ryP	NGfNbGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5N\|U4Pid-MkWyPVM2PzZ:L3G+
RMG2	M13MeWFxd3C2b4Ppd{BCe3O\|YYm=	NXf0eJMzOzBizszN	NHP1b\|gzPCCq	NHTmVGVqdmS3Y3XzJIFxd3C2b4Ppdy=>	M1nSXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUG5NVQ5Lz5{NUWxPVE1QDxxYU6=
RMG1	MXjBdI9xfG:\|aYOgRZN{e2G7	NVLjZVQyOzBizszN	M3TDbFI1KGh?	M{G0NIlv\HWlZYOgZZBweHSxc3nz	M{HpZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUG5NVQ5Lz5{NUWxPVE1QDxxYU6=
A2780	M1GyPWNmdGxiVnnhZoltcXS7IFHzd4F6	MV6xMVMxKM7:TR?=	M4nHcVQ5KGh?	M{G1eoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTVzOUG0PEc,OjV3MUmxOFg9N2F-
SKOV3	NX3mVYpCS2WubDDWbYFjcWyrdImgRZN{[Xl?	MU[xMVMxKM7:TR?=	M1zaUFQ5KGh?	NIGyd4pl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	NWHyW2ExRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NVkyPDhpPkK1OVE6OTR6PD;hQi=>
OVISE	Mn7UR4VtdCCYaXHibYxqfHliQYPzZZk>	Ml:5NU0{OCEQvF2=	Mn74OFghcA>?	MVLk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	M3zVd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUG5NVQ5Lz5{NUWxPVE1QDxxYU6=
RMG2	M3ixUWNmdGxiVnnhZoltcXS7IFHzd4F6	NHXCfnoyNTNyIN88US=>	MmTUOFghcA>?	NGGw[XVl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTVzOUG0PEc,OjV3MUmxOFg9N2F-
HAC2	NXfhOm0{S2WubDDWbYFjcWyrdImgRZN{[Xl?	M{O1d\|EuOzBizszN	MljpO\|IhcA>?	M2\tUYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	NV;BTnRNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NVkyPDhpPkK1OVE6OTR6PD;hQi=>
KOC7C	MVrD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	Mny0NU0{OCEQvF2=	MlzYO\|IhcA>?	MX;k[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTVzOUG0PEc,OjV3MUmxOFg9N2F-
RMG2	MUTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MWGxMVMxKM7:TR?=	MVW3NkBp	MVPk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NEDnT4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWxPVE1QCd-MkW1NVkyPDh:L3G+
RMG1	NW[yTIhwS2WubDDWbYFjcWyrdImgRZN{[Xl?	MoXpNU0{OCEQvF2=	MVi3NkBp	M2nlS4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	M1:3VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUG5NVQ5Lz5{NUWxPVE1QDxxYU6=
H460	Moe3SpVv[3Srb36gRZN{[Xl?	NGrxVmI{KM7:TR?=	NX;zd25{QCCq	Mmm2Zoxw[2u\|IH3UU3JEOSxiYX7kJGVTUy2PQWDLJIFkfGm4YYTpc44h[2:vYnnu[YQhf2m2aDDNSWsuOTZ{	Mnn0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4OUe4PVkoRjJ3Nkm3PFk6RC:jPh?=
A549	MUnGeY5kfGmxbjDBd5NigQ>?	MmjxN{DPxE1?	MVm4JIg>	NHfWeYtjdG:la4OgcXRQWkNzLDDhcoQhTVKNLV3BVGsh[WO2aY\heIlwdiClb33ibY5m\CC5aYToJG1GUy1zNkK=	NXvORpl6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2PVc5QTlpPkK1Olk4QDl7PD;hQi=>
H460	NXjZcZVITnWwY4Tpc44hSXO\|YYm=	Ml;6N{DPxE1?	MkjZPEBp	M1K3OoJtd2OtczDBT3Qh[WO2aY\heIlwdg>?	NV7BcJdDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2PVc5QTlpPkK1Olk4QDl7PD;hQi=>
A549	M2frUmZ2dmO2aX;uJGF{e2G7	MkX3N{DPxE1?	NV\uPHV[QCCq	NYnBdnBs[myxY3vzJGFMXCCjY4TpeoF1cW:w	NXvBSFVMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2PVc5QTlpPkK1Olk4QDl7PD;hQi=>
H460	NF;rSWNCeG:ydH;zbZMhSXO\|c3H5	NYjLfXhNOS9\|IN88US=>	MknuOFghcA>?	MXjpcoR2[2W\|IHHwc5B1d3Orcx?=	MnfXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4OUe4PVkoRjJ3Nkm3PFk6RC:jPh?=
A549	NFj5VoFCeG:ydH;zbZMhSXO\|c3H5	M{\XXFEwOyEQvF2=	Mm\iOFghcA>?	NF2ze3ZqdmS3Y3XzJIFxd3C2b4Ppdy=>	NVnNVlZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2PVc5QTlpPkK1Olk4QDl7PD;hQi=>
H460	M4rEWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWW0NYlwOC5\|LUGwJO69VQ>?	Mke2NlQwPzJiaB?=	MYTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ7N{i5PUc,OjV4OUe4PVk9N2F-
A549	NEG1dXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW[wMlMuOTBizszN	M2XkXVI1Nzd{IHi=	NUXjOXp1cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ7N{i5PUc,OjV4OUe4PVk9N2F-
U-87 MG	M3nwUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPjTYtjOjBxNECg{txO	MmDXNlQwPDhiaB?=	M3qzWYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl\|NEKzNkc,OjV7M{SyN\|I9N2F-
HepG2	MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nMOVIxNzRyIN88US=>	NV25TYpWOjRxNEigbC=>	Ml;0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl\|NEKzNkc,OjV7M{SyN\|I9N2F-
U-87 MG	NGLsVmtHfW6ldHnvckBCe3OjeR?=	NVLLO3FxOjEEoN88US=>	NGm2XGU3NzJ2IHi=	M33hcolv[3KnYYPld{B1cGViYYX0c5Bp[WerYzDmcJV5KCCjdDC2JIghf2irbHWgbY5pcWKrdIOgeIhqeyCobIX4JIF1KDJ2aB?=	NYfXZpJZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5N\|QzOzJpPkK1PVM1OjN{PD;hQi=>
HepG2	M1HDTWZ2dmO2aX;uJGF{e2G7	NHXBbWYzOMLizszN	NX\WNVNLPi9{NDDo	MWrk[YNz\WG\|ZYOgUGM{NUmLIHTl[5Ji\GG2aX;uxsBnem:vIE[gbC=>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl\|NEKzNkc,OjV7M{SyN\|I9N2F-
U-87 MG	MV;GeY5kfGmxbjDBd5NigQ>?	M33mTlIxyqEQvF2=	NUnIUZY6Pi9{NDDo	MmTPbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZiTFOzMWlKKGOxdILlZZRm\CC5aYToJGNS	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl\|NEKzNkc,OjV7M{SyN\|I9N2F-
HepG2	MVrGeY5kfGmxbjDBd5NigQ>?	NV;LfG86OjEEoN88US=>	M{PUO\|YwOjRiaB?=	NVPjUWVCcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gUGM{NUmLIHPveJJm[XSnZDD3bZRpKEOT	NUjCblhXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5N\|QzOzJpPkK1PVM1OjN{PD;hQi=>
U-87 MG	M1m2N2Z2dmO2aX;uJGF{e2G7	NXTC[W5POjEEoN88US=>	NInUfZozPMLiaB?=	Mk\WbY5kemWjc3XzJIRwfWKuZT3t[Y1jemGwZTDic5Vv\CC\|dIL1Z5R2emW\|	MkPSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7M{SyN\|IoRjJ3OUO0NlMzRC:jPh?=
HepG2	M{PaPWZ2dmO2aX;uJGF{e2G7	NIH2PXgzOMLizszN	MlLxNlTDqGh?	M{naeZBzd2S3Y3XzJIFvKGmwdHXud4Uh[3m2b4DsZZNucWNidnHjeY9tcXqjdHnvckBkd3K{ZYPwc45lcW6pIITvJIEhdm:2YXLs[UBlcWyjdHH0bY9vKG:oIITo[UBGWiClaYP0[ZJvew>?	NVu2cIYxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5N\|QzOzJpPkK1PVM1OjN{PD;hQi=>
T24 BC	NX6zbpp3SXCxcITvd4l{KEG\|c4PhfS=>	MUmyMlUh\|ryP	MWeyOEBp	MX3z[Y5{cXSrenXzJGJEKGOnbHzzJJRwKHOxcnHm[Y5q[i2rbnT1Z4VlKGGyb4D0c5Rq[8Li	NVKwfm55RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPVc5PzNpPkK2NFk4QDd\|PD;hQi=>
T24 BC	M4r3b2NmdGxiVnnhZoltcXS7IFHzd4F6	NIDwfHQxNjVxMT:yMlUh\|ryP	NFHORWEzPCCq	NWflVIJW\W6qYX7j[ZMhe2:{YX\lcoljNWmwZIXj[YQh[2WubDD2bYFjcWyrdImg[IVkemWjc3W=	NFv1[JM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC5O\|g4Oyd-Mk[wPVc5PzN:L3G+
T24 BC	MnLkSpVv[3Srb36gRZN{[Xl?	M4jjdlAvPS9zL{KuOUDPxE1?	NWjvT4RJOyCq	MWry[YR2[2W\|IITo[UBj[XOjbDDDRkB1gXKxc3nu[UBxcG:\|cHjvdplt[XSrb36gcIV3\Wy\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB7N{i3N{c,OjZyOUe4O\|M9N2F-
RBL2H3	MmDNSpVv[3Srb36gZZN{[Xl?			M2r3eXRwgGmlaYT5JIlvKHKjdDDSRmwzUDNiY3XscJMtKE2WRE2yOe69VQ>?	MoH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNUO1OlUoRjJyMUWzOVY2RC:jPh?=
PC3	MkezS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			M2PXSWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHBEOyClZXzsd{BjgSC\|dXzmc5Jpd2SjbXnu[UBDKGG\|c3H5MEBIUTVyPUCuOFTPxE1?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTV2M{G0NUc,OjF3NEOxOFE9N2F-
NUGC3	MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NWnjSXRQT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVlWJQ{OgZ4VtdHNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiR1m1NF0xNjV2zszN	Mn\6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3NEOxOFEoRjJzNUSzNVQyRC:jPh?=
HCT15	NYXa[VBWT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M4[3SGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhEXDF3IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZktKEeLNUC9NU4zPc7:TR?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTV2M{G0NUc,OjF3NEOxOFE9N2F-
MDA-MB-231	MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NInpb3FIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIJ6KHO3bH\vdohw\GGvaX7lJGIh[XO\|YYmsJGdKPTB;Mj64Ou69VQ>?	NIHUXpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUW0N\|E1OSd-MkG1OFMyPDF:L3G+
NCI-H23	MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			Ml\2S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUmNKNUh{MzDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCJSUWwQVQvOjIQvF2=	MkfIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3NEOxOFEoRjJzNUSzNVQyRC:jPh?=
ACHN	NHHNfHdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NF;CV\|hIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBCS0iQIHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZktKEeLNUC9OE42Ps7:TR?=	MnvuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3NEOxOFEoRjJzNUSzNVQyRC:jPh?=
A549	NI\od2RHfW6ldHnvckBie3OjeR?=		NYn6blg3OzBibXnudy=>	Ml7sTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIHnuJIlve3WuaX6td5RqdXWuYYTl[EBpfW2jbjDBOVQ6KGOnbHzzJJRz\WG2ZXSgNkBpenNiYnXmc5JmKGmwc4XsbY4he3SrbYXsZZRqd25ibXXhd5Vz\WRiYX\0[ZIhOzBibXnud{BjgSCHTFnTRUwhUUN3ME21MlPPxE1?	NXjwZ4RzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxN\|g{ODlpPkKyNVM5OzB7PD;hQi=>
A549	MoLvR5l1d3SxeHnjbZR6KGG\|c3H5		NVLKUGFzOjRiaILz	M{LmbWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgNlQhcHK\|IHL5JGZCS1NiYX7hcJl{cXNuIFnDOVA:P87:TR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF\|OEOwPUc,OjJzM{izNFk9N2F-
KATO III	NHP1Z2lEgXSxdH;4bYNqfHliYYPzZZk>		MX[yOEBpenN?	MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRXRQKEmLSTDj[YxteyCjZoTldkAzPCCqcoOgZpkhTkGFUzDhcoFtgXOrczygTWM2OD1zMj64{txO	NWDiOFAzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxN\|g{ODlpPkKyNVM5OzB7PD;hQi=>
MCF7	M3;SU2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NUPWVJFrOjRiaILz	NHXpWFBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFI1KGi{czDifUBHSUOVIHHuZYx6e2m\|LDDJR\|UxRTF\|LkROwG0>	M2fZflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUO4N\|A6Lz5{MkGzPFMxQTxxYU6=
PC3	NIf2dW9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MXHHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDQR\|Mh[2WubIOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvPDUQvF2=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ4NkG4NUc,OjN{Nk[xPFE9N2F-
NUGC3	NW\ET3pxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NXnkOXJJT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVlWJQ{OgZ4VtdHNiYomgV3JDKGG\|c3H5MEBIUTVyPUCuOVTPxE1?	M1L0c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|Mk[2NVgyLz5{M{K2OlE5OTxxYU6=
HCT15	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NV71O5QyT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWMUWgZ4VtdHNiYomgV3JDKGG\|c3H5MEBIUTVyPUGuNlXPxE1?	MmrBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{Nk[xPFEoRjJ\|Mk[2NVgyRC:jPh?=
MDA-MB-231	MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M1zQR2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZpkhW1KEIHHzd4F6NCCJSUWwQVIvQDcQvF2=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ4NkG4NUc,OjN{Nk[xPFE9N2F-
NCI-H23	MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MUTHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDJ\|IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD12LkKx{txO	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ4NkG4NUc,OjN{Nk[xPFE9N2F-
ACHN	MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MV3Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDBR2hPKGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NF01NjV4zszN	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ4NkG4NUc,OjN{Nk[xPFE9N2F-
A549	NELYU\|RHfW6ldHnvckBie3OjeR?=		M1za[FIhcHK\|	M{XUOGlvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDpcpN2dGmwLYP0bY12dGG2ZXSgRVU1QSClZXzsd{BqdmO3YnH0[YQh\m:{IEKgbJJ{KHC{aX;yJJRwKGmwc4XsbY4ucW6mdXP0bY9vKG2nYYP1doVlKGGodHXyJFMxKG2rboOgZpkhTUyLU1GsJGlEPTB;NT6z{txO	MkfXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUWwPFMoRjJ\|NEG1NFg{RC:jPh?=
A549	MULDfZRwfG:6aXPpeJkh[XO\|YYm=			MVfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIJ6KG[ub4egZ5l1d22ndILpZ{BidmGueYPpd{whUUN3ME23{txO	MlzMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUWwPFMoRjJ\|NEG1NFg{RC:jPh?=
KATO III	MWXDfZRwfG:6aXPpeJkh[XO\|YYm=			NXOxWIw3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU0GWTzDJTWkh[2WubIOgZpkh\myxdzDjfZRwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyPUGyMljPxE1?	NILTbng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxOVA5Oyd-MkO0NVUxQDN:L3G+
MCF7	MV\DfZRwfG:6aXPpeJkh[XO\|YYm=			MlfzR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BjgSCobH;3JIN6fG:vZYTybYMh[W6jbInzbZMtKEmFNUC9NVMvO87:TR?=	MnTyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUWwPFMoRjJ\|NEG1NFg{RC:jPh?=
PC3	M{mxPGFvfGmycn;sbYZmemG2aY\lJIF{e2G7			MkDKRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCSQ{OgZ4VtdHNiYomgV3JDKGG\|c3H5MEBIUTVyPUCuOFTPxE1?	MmPZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3Nke5OVAoRjJ\|NU[3PVUxRC:jPh?=
NUGC3	M{DvXGFvfGmycn;sbYZmemG2aY\lJIF{e2G7			NUD1bZN[SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOWWdEOyClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:OC53NN88US=>	NUfs[Y1LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1Olc6PTBpPkKzOVY4QTVyPD;hQi=>
HCT15	NGLSZ2ZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			NE\EW2RCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFE2KGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NF0yNjJ3zszN	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV4N{m1NEc,OjN3Nke5OVA9N2F-
MDA-MB-231	M2XYPGFvfGmycn;sbYZmemG2aY\lJIF{e2G7			MX\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxRTJwOEdOwG0>	NXG3W\|lJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1Olc6PTBpPkKzOVY4QTVyPD;hQi=>
NCI-H23	NUjhd2xnSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			NVjNNXNLSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDJ\|IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD12LkKx{txO	MonkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3Nke5OVAoRjJ\|NU[3PVUxRC:jPh?=
ACHN	NELmenpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			MkX3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDQ1jOJINmdGy\|IHL5JHNTSiCjc4PhfUwhT0l3ME20MlU3\|ryP	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV4N{m1NEc,OjN3Nke5OVA9N2F-
PC3	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NV;lc2NpPDhiaILz	MlfrS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmsJGdKPTB;MD60OO69VQ>?	NXTMVJQyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVU4PTlpPkK0NFk2PzV7PD;hQi=>
NUGC3	MkiyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NFLEdoQ1QCCqcoO=	M1XCcWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5WT0N\|IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9NE42PM7:TR?=	NYnUZ5J7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVU4PTlpPkK0NFk2PzV7PD;hQi=>
HCT15	MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXG0PEBpenN?	MVvHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR3QyPSClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBIUTVyPUGuNlXPxE1?	M{nvTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEm1O\|U6Lz5{NEC5OVc2QTxxYU6=
MDA-MB-231	NYnpcncyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M{LET\|Q5KGi{cx?=	NGX1TWNIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmsJGdKPTB;Mj64Ou69VQ>?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7NUe1PUc,OjRyOUW3OVk9N2F-
NCI-H23	M3W2[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{TQc\|Q5KGi{cx?=	MWPHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDJ\|IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9OE4zOc7:TR?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7NUe1PUc,OjRyOUW3OVk9N2F-
ACHN	M4roUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NYn0VY5FPDhiaILz	NU[wTZV[T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hSUOKTjDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVQvPTcQvF2=	NUnzO4RCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVU4PTlpPkK0NFk2PzV7PD;hQi=>
A549	M4L3PGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NELJZXAzPCC2bzC3NkBpenN?	M3robGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgNlQhfG9iN{KgbJJ{KGK7IHjh[Y1w[3m2b33leJJ6NCCLQ{WwQVQvOTgQvF2=	M2XqdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwOlIxLz5{NEmwNFYzODxxYU6=
Rosetta cells	MXTGeY5kfGmxbjDhd5NigQ>?			M3nrd2lvcGmkaYTpc44hd2Zid3ns[E11gXCnIHj1cYFvKFB\|OHHsdIhiKE2DUFug[ZhxemW\|c3XkJIlvKEW\|Y3jldolkcGmjIHPvcIkhWm:\|ZYT0ZUBk\WyuczygTWM2OD1zLkNOwG0>	NGGyNYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MUK3OFMyPid-M{GyO\|Q{OTZ:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-PDK1 / p-GSK3α/β / p-S6R ; PubMed: 17761832 Blood BCWM.1 cells were cultured with perifosine for 6 hours with doses that ranged from 2 to 20 μM. Whole cell lysates were subjecting to Western blotting using anti–p-Akt ser473, -Akt, –p-PDK1, –p-GSK3α/β, –p-S6R, and α-tubulin antibodies. p-mTOR / mTOR / Raptor / Rictor / p-p70S6K / p70S6K / p-4EBP1 / 4EBP1 / c-Myc / Cyclin D1; PubMed: 19920197 Cancer Res The indicated cell lines were treated with the given concentrations of perifosine (PRFS) for 8 h. PARP; PubMed: 25519148 Mol Cancer Res Perifosine induces apoptosis. RMG1 and RMG2 cells were treated with or without 30 μM perifosine for 24 h. Cells were harvested, and the effect of perifosine was evaluated by western blotting p-AKT / AKT / p-S6K1 / S6K1 ; PubMed: 25519148 Mol Cancer Res The effect of perifosine on AKT-mTOR activation in vitro. RMG1 and RMG2 cells were treated with 0, 3, 10, 30 or 50 μM perifosine for 6 h in the presence of 10% FBS. Cells were harvested, and equivalent amounts (30 μg) of protein were subjected to SDS-PAGE and blotted with anti-phospho-AKT (Ser473), anti-AKT, anti-phospho-S6K1 (Thr389), anti-S6K1, or anti-β-actin antibodies.	17761832 19920197 25519148
Growth inhibition assay	Cell viability; PubMed: 28332584 Sci Rep Cell survival measured by MTT assay and IC50 of perifosine in a panel of eleven human cancer cells.	28332584

In vivo

Perifosine combining with temozolomide reduces tumor proliferation (a PDGF-driven gliomagenesis) in vivo. The results indicate that Perifosine is an effective drug in gliomas in which Akt and Ras-Erk 1/2 pathways are frequently activated, and may be new candidate for glima treatment in the clinic. ^[2] Both oral daily and weekly administration of Perifosine significantly reduce human MM tumor growth and increase survival, compared with control animals treated with PBS vehicle only. ^[3] Perifosine induces thrombocytosis and leukocytosis and increases myelopoiesis in murine marrow and spleen, whereas it causes apoptosis in myeloma xenografts. ^[5]

Protocol

Kinase Assay:^[3]	- Collapse Akt kinase assay: MM.1S cells are cultured in the presence or absence of perifosine (5 μM, 6 hours) and then stimulated with IL-6 (20 ng/mL, 10 minutes). In vitro akt kinase assay is then carried out using the Akt Kinase Assay Kit.
Cell Research:^[2]	- Collapse Cell lines: Human glioma cell lines Concentrations: 0, 15, 30 and 45 μM Incubation Time: 48 hours Method: Cells are incubated in the medium with 10% FCS for 48 hours with indicated concentration of Periosine. Cell viability is determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (Cell Proliferation Kit I; Roche). The absorbance at 590 nm is recorded using the 96-well plate reader. (Only for Reference)
Animal Research:^[3]	- Collapse Animal Models: MM.1S MM cells are inoculated subcutaneously in the right flank of Beige-nude-xid (BNX) mice (5 to 6 weeks old). Dosages: 250 mg/kg/wk or 36 mg/kg/d Administration: Oral gavage (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	Water	8 mg/mL (17.32 mM)
	DMSO	Insoluble
	Ethanol	'15 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): water For best results, use promptly after mixing.	8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Perifosine (KRX-0401) SDF

Molecular Weight	461.66
Formula	C₂₅H₅₂NO₄P
CAS No.	157716-52-4
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	NSC639966, D21266
Smiles	CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](CC1)(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01224730	Completed	Drug: perifosine	Cancer	AEterna Zentaris	January 24 2012	Phase 1
NCT01049841	Completed	Drug: perifosine + temsirolimus	Pediatric Solid Tumors	Memorial Sloan Kettering Cancer Center\|University of Wisconsin Madison\|Duke University\|NATL COMP CA NETWORK\|Pfizer\|AEterna Zentaris	January 2010	Phase 1
NCT01048580	Completed	Drug: Perifosine\|Drug: Capecitabine	Colon Cancer	AEterna Zentaris\|SCRI Development Innovations LLC	October 2009	Phase 1
NCT00776867	Completed	Drug: perifosine	Solid Tumors	Memorial Sloan Kettering Cancer Center\|University of Wisconsin Madison\|Duke University\|AEterna Zentaris	October 2008	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Selective Akt Inhibitor

CCT128930 : AKT2-selective, IC50=6 nM.
Most Potent Akt Inhibitor

AZD5363 : Akt1, IC50=3 nM; Akt2, IC50=8 nM; Akt3, IC50=8 nM.
Akt Inhibitor in Clinical Trial

Ipatasertib (GDC-0068) : Phase II for Prostate Cancer and Gastric Cancer.
Newest Akt Inhibitor

AZD5363 : Potent inhibitor of all isoforms of Akt (Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM, similar to P70S6K/PKA and lower activity towards ROCK1/2.

Related Akt Products

Afuresertib (GSK2110183) ^New

Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with K_i of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.
AT13148 ^New

AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.
SC79 ^New

SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. MK-2206 2HCl induces autophagy and apoptosis in cancer cells. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
Capivasertib (AZD5363)

Capivasertib (AZD5363) potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.
Ipatasertib (GDC-0068)

Ipatasertib (GDC-0068, RG7440) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.
GSK690693

GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. GSK690693 also potently inhibits AMPK and DAPK3 from the CAMK family with IC50 of 50 nM and 81 nM, respectively. GSK690693 affects Unc-51-like autophagy activating kinase 1 (ULK1) activity, robustly inhibits STING-dependent IRF3 activation. Phase 1.
Triciribine (NSC 154020)

Triciribine (NSC 154020, VD-0002, vqd-002, API-2, TCN) is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.
Honokiol (NSC 293100)

Honokiol (NSC 293100) is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Honokiol causes G0/G1 phase arrest, induces apoptosis, and autophagy via the ROS/ERK1/2 signaling pathway. Honokiol inhibits hepatitis C virus (HCV) infection. Phase 3.

Choose Your Country or Region

By Signaling Pathways

By product type

Perifosine (KRX-0401)